Suppr超能文献

芳香基丙酸衍生物过敏反应的诊断评估:一项描述性观察研究,重点关注儿童的临床特征和潜在危险因素。

Diagnostic evaluation of hypersensitivity reactions to arylpropionic acid derivatives: a descriptive observational study focusing on clinical characteristics and potential risk factors in children.

机构信息

Department of Pediatric Allergy and Immunology, Faculty of Medicine, Mersin University, Çiftlikköy Kampüsü, Yenişehir, Mersin, Turkey.

Department of Pediatric Allergy and Immunology, Adıyaman University Training and Research Hospital, Adıyaman, Turkey.

出版信息

Int J Clin Pharm. 2024 Dec;46(6):1294-1306. doi: 10.1007/s11096-024-01756-4. Epub 2024 Jun 11.

Abstract

BACKGROUND

Arylpropionic acid derivatives (APs) are the main triggers of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity. Data on clinical patterns and risk factors for AP hypersensitivity in children are quite limited.

AIM

To assess the clinical characteristics and potential risk factors for proven AP hypersensitivity in children.

METHOD

Patients with a history of AP hypersensitivity were retrospectively assessed using a standardized diagnostic algorithm. Children with confirmed hypersensitivity were defined as selective responders or cross-intolerants based on the result of drug provocation tests and further categorized according to the EAACI/ENDA classification. A multivariable logistic regression analysis was performed to analyze the potential risk factors for proven AP hypersensitivity.

RESULTS

A total of 166 patients (51.2% male, median age of six years) with a history of AP hypersensitivity were included. Ibuprofen (89.2%) was the most frequently reported AP in the patients' histories. The reported hypersensitivity of 40 (22.4%) patients was confirmed by diagnostic testing: eight (13.6%) patients with a history of reaction only to APs and 32 (29.9%) patients with a history of reactions to multiple NSAIDs, including chemically unrelated NSAIDs in addition to APs. Five (12.5%) patients were classified as selective responders and 35 (87.5%) were cross-intolerants. Overall, five (12.5%) of the confirmed cases could not be categorized according to the EAACI/ENDA classification. Older age (aOR: 1.11, 95% CI 1.02-1.21, p = 0.015), chronic urticaria as an underlying disease (aOR: 2.87, 95% CI 1.09-7.54, p = 0.033) and a history of anaphylaxis (aOR: 7.84, 95% CI 1.86-33.04, p = 0.005) were related to confirmed AP hypersensitivity.

CONCLUSION

Almost a quarter of children and adolescents were confirmed to have AP hypersensitivity. Older age, the presence of chronic urticaria and a history of anaphylaxis were potential risk factors for proven AP hypersensitivity.

摘要

背景

芳基丙酸衍生物(APs)是引发非甾体抗炎药(NSAID)过敏的主要原因。关于儿童中芳基丙酸衍生物过敏的临床模式和危险因素的数据相当有限。

目的

评估儿童中已证实的芳基丙酸衍生物过敏的临床特征和潜在危险因素。

方法

采用标准化诊断算法对有芳基丙酸衍生物过敏史的患者进行回顾性评估。根据药物激发试验的结果,将确诊的过敏患者定义为选择性反应者或交叉不耐受者,并根据 EAACI/ENDA 分类进一步分类。采用多变量逻辑回归分析来分析已证实的芳基丙酸衍生物过敏的潜在危险因素。

结果

共纳入 166 例(51.2%为男性,中位年龄为 6 岁)有芳基丙酸衍生物过敏史的患者。在患者的病史中,布洛芬(89.2%)是最常报告的芳基丙酸衍生物。40 例(22.4%)患者的过敏反应通过诊断性检查得到证实:8 例(13.6%)患者仅对芳基丙酸衍生物过敏,32 例(29.9%)患者对多种 NSAIDs 过敏,除芳基丙酸衍生物外还包括化学结构不同的 NSAIDs。5 例(12.5%)患者被归类为选择性反应者,35 例(87.5%)为交叉不耐受者。总体而言,5 例(12.5%)确诊病例无法根据 EAACI/ENDA 分类进行分类。年龄较大(比值比:1.11,95%置信区间 1.02-1.21,p=0.015)、慢性荨麻疹作为潜在疾病(比值比:2.87,95%置信区间 1.09-7.54,p=0.033)和过敏反应史(比值比:7.84,95%置信区间 1.86-33.04,p=0.005)与已证实的芳基丙酸衍生物过敏有关。

结论

近四分之一的儿童和青少年被证实有芳基丙酸衍生物过敏。年龄较大、存在慢性荨麻疹和过敏反应史是已证实的芳基丙酸衍生物过敏的潜在危险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验